News
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
EQS-News: Evotec SE to announce results for the first nine months 2023 on 08 November 2023
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a
Merck (MRK) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q3 2023 Earnings CallOct 26, 2023, 9:00 a.m. ET
Operator
Source Fool.com
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
3 Safe Dividend Stocks to Beat Inflation
Like it or not, inflation remains higher than Americans have been accustomed to, and the impacts of last year's price surge have not gone away. As of September, inflation as measured by the Consumer
EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
EQS-News: Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
3 Reasons to Buy Merck Stock
Pharmaceutical giant Merck (NYSE: MRK) has delivered excellent returns to its shareholders over the past 12 months, as last year's downturn did little to slow the drugmaker. The company's solid
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
The US harvests
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
The US harvests
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
EQS-News: MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Better Pharma Growth Stock: Eli Lilly vs. Merck
Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) are both among the largest biopharmaceutical businesses in the world, but their growth prospects aren't exactly the same. Nonetheless, the pair handily
EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates
EQS-News: Evotec SE reports first half-year 2023 results on 29 August 2023
My Oh My, Merck Stock Is a No-Brainer Income Stock to Buy
Investing for income may never be the most exciting investment strategy in the world. But as long as a company doesn't cut or suspend its dividend, it can be a profitable approach -- and some